Taylor A Cook, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 620 N Putnam St, Moweaqua, IL 62550 Phone: 217-528-7541 Fax: 217-768-3811 |
News Archive
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
Cedric, a captive born Tasmanian devil climbed to fame in 2007 when it was shown that he was genetically resistant to facial tumors. Initially he and his half-brother Clinky were given a vaccine of sorts containing dead tumor cells and later "challenged" with live tumor cells by the University of Tasmania researchers in 2007. Clinky developed the cancer, but Cedric did not - starting hopes that he had an immunity that could help scientists develop a vaccine.
› Verified 5 days ago